David Maggs

7.0k total citations · 2 hit papers
72 papers, 5.4k citations indexed

About

David Maggs is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, David Maggs has authored 72 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Endocrinology, Diabetes and Metabolism, 27 papers in Surgery and 17 papers in Molecular Biology. Recurrent topics in David Maggs's work include Diabetes Treatment and Management (43 papers), Diabetes Management and Research (34 papers) and Pancreatic function and diabetes (25 papers). David Maggs is often cited by papers focused on Diabetes Treatment and Management (43 papers), Diabetes Management and Research (34 papers) and Pancreatic function and diabetes (25 papers). David Maggs collaborates with scholars based in United States, United Kingdom and Australia. David Maggs's co-authors include Orville Kolterman, Mark Fineman, Loretta L. Nielsen, John B. Buse, John H. Holcombe, S. Strobel, Christian Weyer, David C. Klonoff, Christopher L. Bowlus and Matthew Wintle and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Annals of Internal Medicine.

In The Last Decade

David Maggs

72 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus

1998 636 citations Silvio E. Inzucchi, David Maggs et al. New England Journal of Medicine profile →
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

2007 597 citations Loretta L. Nielsen, John H. Holcombe et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Maggs United States	36	3.8k	1.9k	1.9k	1.1k	825	72	5.4k
Dennis Dong Hwan Kim Canada	26	5.1k 1.3×	2.4k 1.2×	2.4k 1.3×	1.1k 1.0×	1.9k 2.3×	210	7.6k
Axel Haupt United States	36	4.3k 1.1×	2.0k 1.0×	1.8k 1.0×	1.5k 1.4×	1.6k 2.0×	108	6.5k
Signe S. Torekov Denmark	30	1.7k 0.4×	1.1k 0.6×	790 0.4×	1.3k 1.2×	605 0.7×	87	3.9k
Yukio Tanizawa Japan	41	1.9k 0.5×	2.6k 1.3×	2.5k 1.3×	763 0.7×	296 0.4×	152	5.9k
Aleksey V. Matveyenko United States	39	2.0k 0.5×	1.8k 0.9×	2.4k 1.3×	1.2k 1.1×	230 0.3×	100	5.1k
Keith D. Kaufman United States	47	6.2k 1.6×	2.8k 1.5×	2.1k 1.1×	671 0.6×	1.2k 1.4×	118	9.3k
Takahisa Hirose Japan	34	2.1k 0.5×	1.3k 0.7×	1.2k 0.6×	845 0.8×	372 0.5×	166	4.8k
Dora M. Berman United States	33	1.4k 0.4×	841 0.4×	2.1k 1.1×	1.1k 1.0×	355 0.4×	69	4.1k
Maria‐Christina Zennaro France	41	3.3k 0.9×	1.8k 1.0×	1.7k 0.9×	565 0.5×	245 0.3×	130	4.9k
Kinori Kosáka Japan	38	2.6k 0.7×	1.3k 0.7×	1.5k 0.8×	911 0.9×	206 0.2×	162	4.8k

Countries citing papers authored by David Maggs

Since Specialization

Citations

This map shows the geographic impact of David Maggs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Maggs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Maggs more than expected).

Fields of papers citing papers by David Maggs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Maggs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Maggs. The network helps show where David Maggs may publish in the future.

Co-authorship network of co-authors of David Maggs

This figure shows the co-authorship network connecting the top 25 collaborators of David Maggs. A scholar is included among the top collaborators of David Maggs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Maggs. David Maggs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ghosh, Soumitra, Francesco Rubino, Pernille Wismann, et al.. (2018). Westernized Diet–Induced Insulin Resistance in Mice Is Associated with Focal Duodenal Hyperplasia. Diabetes. 67(Supplement_1). 6 indexed citations

Maggs, David & John Robinson. (2016). Recalibrating the Anthropocene. Environmental Philosophy. 13(2). 175–194. 21 indexed citations

Herrmann, Kathrin, Steven C. Brunell, Yan Li, Ming Zhou, & David Maggs. (2016). Impact of Disease Duration on the Effects of Pramlintide in Type 1 Diabetes: A Post Hoc Analysis of Three Clinical Trials. Advances in Therapy. 33(5). 848–861. 11 indexed citations

Wysham, Carol, Leigh MacConell, David Maggs, et al.. (2015). Five-Year Efficacy and Safety Data of Exenatide Once Weekly. Mayo Clinic Proceedings. 90(3). 356–365. 47 indexed citations

Fineman, Mark, Brenda Cirincione, David Maggs, & M. Diamant. (2012). GLP‐1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obesity and Metabolism. 14(8). 675–688. 95 indexed citations

Paul, Sanjoy K., James D. Best, Kerenaftali Klein, J. Han, & David Maggs. (2012). Effects of HbA _1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide ^*. Diabetes Obesity and Metabolism. 14(9). 826–834. 12 indexed citations

Boye, Kristina S., et al.. (2011). Cardiovascular outcomes associated with a new once‐weekly GLP‐1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis. Diabetes Obesity and Metabolism. 13(10). 921–927. 13 indexed citations

Samsom, Melvin, Adil E. Bharucha, John E. Gerich, et al.. (2009). Diabetes mellitus and gastric emptying: questions and issues in clinical practice. Diabetes/Metabolism Research and Reviews. 25(6). 502–514. 35 indexed citations

Ratner, Robert E., David Maggs, Loretta L. Nielsen, et al.. (2006). Long‐term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over‐weight metformin‐treated patients with type 2 diabetes mellitus. Diabetes Obesity and Metabolism. 8(4). 419–428. 180 indexed citations

10.

Riddle, Matthew C., Robert R. Henry, Terri Poon, et al.. (2006). Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes/Metabolism Research and Reviews. 22(6). 483–491. 91 indexed citations

11.

Maggs, David, Mark Fineman, Sherwyn Schwartz, et al.. (2004). Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose‐timing study. Diabetes/Metabolism Research and Reviews. 20(1). 55–60. 61 indexed citations

12.

Hollander, Priscilla, David Maggs, James A. Ruggles, et al.. (2004). Effect of Pramlintide on Weight in Overweight and Obese Insulin‐Treated Type 2 Diabetes Patients. Obesity Research. 12(4). 661–668. 141 indexed citations

13.

Ratner, Robert E., Richard A. Dickey, Mark Fineman, et al.. (2004). Amylin replacement with pramlintide as an adjunct to insulin therapy improves long‐term glycaemic and weight control in Type 1 diabetes mellitus: a 1‐year, randomized controlled trial. Diabetic Medicine. 21(11). 1204–1212. 219 indexed citations

14.

Hollander, Priscilla, Robert E. Ratner, Mark Fineman, et al.. (2003). Addition of pramlintide to insulin therapy lowers HbA _1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obesity and Metabolism. 5(6). 408–414. 47 indexed citations

15.

Fineman, Mark, C. Weyer, David Maggs, S. Strobel, & Orville Kolterman. (2002). The Human Amylin Analog, Pramlintide, Reduces Postprandial Hyperglucagonemia in Patients with Type 2 Diabetes Mellitus. Hormone and Metabolic Research. 34(9). 504–508. 119 indexed citations

16.

Inzucchi, Silvio E., et al.. (1998). Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus. New England Journal of Medicine. 338(13). 867–873. 636 indexed citations breakdown →

17.

Maggs, David. (1996). Can hypoglycaemia be predicted before its onset? (Comment). Diabetologia. 39(5). 615–617. 2 indexed citations

18.

Maggs, David, Ralph Jacob, Frances Rife, et al.. (1995). Interstitial fluid concentrations of glycerol, glucose, and amino acids in human quadricep muscle and adipose tissue. Evidence for significant lipolysis in skeletal muscle.. Journal of Clinical Investigation. 96(1). 370–377. 136 indexed citations

19.

Maggs, David, Ian Macdonald, & R. B. Tattersall. (1994). Thermoregulatory responses to hyperinsulinaemic hypoglycaemia and euglycaemia in IDDM. Diabetologia. 37(7). 689–696. 7 indexed citations

20.

Maggs, David, et al.. (1994). Thermoregulatory responses to hyperinsulinemic hypoglycemia and euglycemia in humans. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 267(5). R1266–R1272. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact